ClinicalTrials.gg
RecruitingNCT06370078Updated Jun 6, 2024

Effect of Early Administration of Albumin 20% Versus Crystalloid

An interventional study of Albumin Human in Septic Shock, sponsored by Egymedicalpedia. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-06-06.

Sponsored by Egymedicalpedia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Shock, Septic with a site in Egypt — 16 open to participants now, 17 under way, 1 of them phase 3. Shock, Septic · Egypt.

Planned enrollment
24th of 37
46 · median 60
Started
2024
with 3 others
No phase
11 of 61
7 open now
Primary completion
2024-11
later than 1 of 16 live
Registered
40th of 61
by date

Among the 61 studies in Shock, Septic with a site in Egypt, this one is the 24th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2024, is one of 11 with no phase, reaches primary completion later than 1 of the 16 other live ones, and was the 40th registered.

Shock, Septic

1,082 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

16 of the 61 studies in Shock, Septic with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Shock, Septic with a site in Egypt, or all of them as a file.
02

Study summary

Sepsis and septic shock are global health problems, leading to a high mortality rate. They are often associated with extremely low blood pressure and multiple organ dysfunctions, which are the main causes of death in critically ill patients. Fluid resuscitation is one of the most critical treatments for patients with sepsis and septic shock.

An early administration of an appropriate fluid to patients is considered the most effective way to increase blood pressure, improve tissue perfusion, and save their lives. Crystalloid fluids are a subset of intravenous solutions composed of mineral salts and other small, water-soluble molecules, including normal, isotonic or hypertonic saline, and various buffered solutions.

Read the detailed description

Crystalloid fluids are a subset of intravenous solutions composed of mineral salts and other small, water-soluble molecules, including normal, isotonic or hypertonic saline, and various buffered solutions.

Colloid solutions are composed of various amounts of substances, for instance, albumin, hydroxyethyl starch, dextran, and gelatine. Although the current international guidelines from the Surviving Sepsis Campaign recommend crystalloids to perform the initial resuscitation, and the replacement with albumin on patients who require substantial amounts of crystalloids, the choice of the best type of resuscitation fluids is still under debate.

Albumin, in addition to its oncotic functions, has a variety of other properties, including binding and transport of various endogenous molecules, anti-inflammatory and anti-oxidative effects, and modulation of nitric oxide metabolism.These properties are particularly relevant in critically ill patients, especially in patients with sepsis.

03

Conditions studied

  • Septic Shock

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of septic shock that meets all the following Criteria: Clinically possible, probable, or microbiologically confirmed infection according to the definitions of the International-Sepsis- Forums (ISF), Despite adequate volume therapy, vasopressors are required to maintain mean arterial pressure (MAP) ≥ 65 mmHg for at least 1 hour, Serum lactate concentration > 2 mmol/l (18 mg/dl) despite adequate volume therapy.
  • Onset of septic shock less than 24 h prior to study inclusion.
  • Women of childbearing age: negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Moribund conditions
  • End of life decisions
  • Previous participation to this trial or any other interventional clinical trial
  • Known to albumin or any component of the trial drug
  • Clinical conditions, where albumin administration may be unfavourable
  • Breast feeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Human Albumin Group

    About 23 patients will be objected for resuscitation with 60 gm (300 ml) human albumin 20% (HA 20%) over 2-3 hours combined usual practice with 30 ml/kg crystalloid.

    Drug: Albumin Human

  • Active comparator
    Control Group

    About 23 patients will be objected for resuscitation with 30 ml/kg crystalloid.

    Drug: Albumin Human

Interventions

  • DrugAlbumins humanStudies of Albumins humanAlbumins human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.

    Also known as: crystalloids

06

What researchers measure

Primary outcomes

  1. Recovery from shock

    A reversal of hypotension (MAP) at the end of the first three hours of the resuscitation period.

    Time frame: 3 Hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Nov 2024, 5 months after the start.

Of 173 interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 17, 2024
StartActual
Jun 1, 2024
Primary completionEst.
Nov 20, 2024
CompletionEst.
Nov 30, 2024
Last update
Jun 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06370078
Lead sponsor
Egymedicalpedia
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Jun 1, 2024
Primary completion
Nov 20, 2024 (estimated)
Completion
Nov 30, 2024 (estimated)
Last update
Jun 6, 2024

Study contacts

Ahmed Abdelhamed Helal, MSC
Contact
Ahmedel3oksh@gmail.com
+201140415513
Noha Yahia Mohamed, Lecturer
Contact
Noha.hgagy@gmail.com
+201001890194
Mohamed Ahmed Mohamed, Professor
study chair · ICU department , Faculty of Medicine, Assuit University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumins human

Start the discussion